Farmer J A
Department of Medicine, Baylor College of Medicine, Ben Taub General Hospital, Houston, Texas 77030, USA.
Am J Cardiol. 1998 Sep 24;82(6A):26M-31M. doi: 10.1016/s0002-9149(98)00594-3.
Little doubt remains about the value of lipid-lowering therapy since publication of the results of large, randomized, controlled trials that show decreased total, as well as coronary, mortality with the use of statins for primary and secondary prevention of coronary artery disease. All of the available statins are effective and safe, but they vary greatly in terms of cost-effectiveness. Fluvastatin has been determined to be a cost-effective therapeutic agent in the large proportion of the population with mild-to-moderate dyslipidemia who fit treatment guidelines of the National Cholesterol Education Program (NCEP). Atorvastatin and simvastatin are cost-effective for the relatively smaller number of patients who require greater reductions in cholesterol.
自从大型随机对照试验结果公布以来，降脂治疗的价值几乎没有疑问。这些试验表明，使用他汀类药物进行冠状动脉疾病的一级和二级预防可降低总死亡率以及冠心病死亡率。所有可用的他汀类药物都是有效且安全的，但它们在成本效益方面差异很大。对于符合美国国家胆固醇教育计划（NCEP）治疗指南的大部分轻度至中度血脂异常人群，氟伐他汀已被确定为一种具有成本效益的治疗药物。阿托伐他汀和辛伐他汀对于需要更大程度降低胆固醇的相对较少患者数量而言具有成本效益。
